Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 3, 2025

Anti-Bcl-xL Antibody, Unconjugated

RRID:AB 10694844

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 2762, RRID:AB_10694844)

Antibody Information

URL: http://antibodyregistry.org/AB_10694844

Proper Citation: (Cell Signaling Technology Cat# 2762, RRID:AB_10694844)

Target Antigen: Bcl-xL

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10694844, AB_329920.

Antibody Name: Anti-Bcl-xL Antibody, Unconjugated

Description: This unknown targets Bcl-xL

Target Organism: monkey, rat, simian, mouse, human

Antibody ID: AB_10694844

Vendor: Cell Signaling Technology

Catalog Number: 2762

Record Creation Time: 20231110T044930+0000

Record Last Update: 20241115T115944+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Bcl-xL Antibody, Unconjugated.

No alerts have been found for Anti-Bcl-xL Antibody, Unconjugated.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

He Y, et al. (2024) Deficient tRNA posttranscription modification dysregulated the mitochondrial quality controls and apoptosis. iScience, 27(2), 108883.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell reports. Medicine, 4(4), 101007.

Abbonante V, et al. (2023) Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis. Autophagy, 19(3), 984.

Popescu B, et al. (2023) Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell reports. Medicine, 4(11), 101290.

Lyu XD, et al. (2023) A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer. Cancers, 15(20).

Baldelli E, et al. (2022) Analysis of neuroendocrine clones in NSCLCs using an immunoguided laser-capture microdissection-based approach. Cell reports methods, 2(8), 100271.

Agrawal Y, et al. (2022) F-box protein FBXO41 plays vital role in arsenic trioxide-mediated autophagic death of cancer cells. Toxicology and applied pharmacology, 441, 115973.

Cao K, et al. (2022) Mitochondrial dynamics regulate genome stability via control of caspase-dependent DNA damage. Developmental cell, 57(10), 1211.

Pesch AM, et al. (2022) Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression. Cancer research communications, 2(7), 679.

Lafferty A, et al. (2021) Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 27(21), 5979.

Aka Y, et al. (2021) Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target. The international journal of biochemistry & cell biology, 137, 106028.

Tanaka K, et al. (2021) Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer cell, 39(9), 1245.

Moustafa-Kamal M, et al. (2020) The mTORC1/S6K/PDCD4/eIF4A Axis Determines Outcome of Mitotic Arrest. Cell reports, 33(1), 108230.

Schütz R, et al. (2020) Synthesis, biological evaluation and toxicity of novel tetrandrine analogues. European journal of medicinal chemistry, 207, 112810.

Fukushima K, et al. (2020) Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis. Immunity, 52(3), 542.

Loo LSW, et al. (2020) BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. Cell death & disease, 11(5), 378.

Shim J, et al. (2020) YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Cancer research, 80(21), 4741.

Zhao X, et al. (2019) BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer cell, 35(5), 752.

Heijink AM, et al. (2019) Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell reports, 28(9), 2345.

Littler S, et al. (2019) Oncogenic MYC amplifies mitotic perturbations. Open biology, 9(8), 190136.